Dr Benjamin Chuah is an oncologist practising at Mount Elizabeth Hospitals, Singapore.
His subspecialty interest is in gastrointestinal cancers including oesophageal, gastric, biliary tract, pancreatic, liver (hepatocellular carcinoma), neuroendocrine and colorectal cancers.
He was previously a consultant in the department of Haematology-Oncology at the National Cancer Institute Singapore, National University Hospital.
Prior to entering private practice, he was actively involved in postgraduate teaching and research. He was the director for postgraduate medical education in medical oncology and was a core faculty for the residency programme for internal medicine.
For his efforts, he was awarded the National University Hospital Postgraduate Teaching Excellence Award in 2011. He was also involved in clinical and translational research for many years and was the principal or co-investigator in international trials involving the use of novel and targeted therapy drugs for colorectal and pancreatic cancer.
Dr Chuah was awarded the NUH Innovative Grant for research in warfarin pharmacogenomics and was honoured the inaugural Kobayashi Foundation Award for work done on serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy. His research work has lead to several 1st author publications in high-impact medical and oncology journals including Gastroenterology, GUT, and Annals of Oncology.
As a clinical cancer specialist and researcher, his research work includes small cell gall bladder cancer with paraneoplastic hyponatremia, exploring the lack of somatic mutations in VEGFR-2 tyrosine kinase domain in hepatocellular carcinoma, renal cell carcinoma (kidney cancer) with bony metastases, and use of the chemotherapy drug docetaxel (Taxotere) with or without ketoconazole in breast cancer.